EndoQuest Robotics closes $42m in financing for advancements in endoluminal robot systems

Medical device company EndoQuest Robotics from Houston, Texas, has announced the successful closure of a $42 million C-1 preferred financing round, with the strategic funding set to help advance its flexible endoluminal robot which is designed to support minimally invasive procedures. 

The company’s legacy investors CE Ventures Limited and McNair Interests Ltd led the financing round along with new investor Puma Venture Capital LLC.

EndoQuest Robotics seeks to support gastrointestinal and other endoluminal surgeries through the development of a robotic system capable of offering precision, flexibility and improved patient outcomes by navigating and performing procedures within the body luminal spaces, “allowing for minimally invasive interventions and enhancing the capabilities of healthcare professionals”.

CEO of EndoQuest Robotics, Kurt Azarbarzin, comments: “Our investors share our vision of leveraging robotics to redefine the possibilities in minimally invasive procedures. This financing enables us to continue innovating and refining our technology, ultimately improving patient care and transforming the future of endoluminal interventions.”

Amit Hazan, co-founder and managing partner of Puma Venture Capital LLC, adds: “I’ve had the privilege of seeing just about every robotic surgical system either in development or on the market today and can honestly say that EndoQuest’s system is a true game changer for both physicians and patients.”

In other news from the USA, we covered how US health tech company Oracle has announced that it will be harnessing generative AI technology to help clinicians reduce administrative pressures.

Additionally, we shared the proposed cybersecurity regulations for hospitals announced by New York State Governor Kathy Hochul.